Make the profile of
Lumea yours.

Company description

Lumea is a digital pathology company headquartered in Lehi, Utah, that develops tissue-handling technology, laboratory information systems, and AI-integrated diagnostic software for pathology practices. Founded by Stanford-trained pathologist Matthew Leavitt, the company was established after its founders identified that existing digital pathology solutions introduced more cost and complexity than they resolved. Lumea's approach begins at the point of specimen acquisition rather than at the scanner, with the goal of connecting clinic, laboratory, and pathology workflows into a single, cohesive system.

Lumea describes itself as the U.S. leader in primary clinical digital pathology by volume of primary digital diagnoses. The company has operated for over a decade, maintains a presence across five continents, and serves more than half of the U.S. urology market, as well as top dermatology and gastroenterology groups nationwide. Its platform has received FDA clearance and is designed to comply with HIPAA, HITECH, and related U.S. data privacy regulations.

Core Products and Modules

• Tissue-handling and histology technology: Proprietary products designed to improve specimen quality, speed turnaround times, enhance RNA testing, and increase cancer detection rates while reducing time, cost, and workflow complexity for laboratory technicians.
• IMS/Viewer: An image management system and slide viewer that handles all small surgical biopsies across specialties, not limited to urology or prostate cases. It integrates with Lumea's tissue technology to create combined lab and pathology efficiencies.
• All-in-one digital pathology-enabled LIS: A laboratory information system that incorporates digital diagnostic tools, one-click molecular testing, and access to an open AI marketplace, all presented on a single screen.
• Consulting services: Implementation support to help practices move from initial interest in digital pathology through to successful deployment, including guidance on vendor selection, ROI planning, and workflow integration.

Key Platform Capabilities

• Specimen tracking from the point of biopsy through laboratory processing and pathologist sign-out.
• Seamless digital sign-out process integrated with laboratory and clinic workflows.
• Access to an open AI marketplace for advanced image analysis, with AI and genetic testing partnerships built into the platform.
• One-click molecular testing accessible within the diagnostic interface.
• Support for remote consultations, reducing the need for physical transportation of slides and personnel.
• Scalability for individual pathologists as well as larger group practices.
• Integration capabilities designed to support collaboration across multiple sites and specialties.

Deployment, Compliance, and Security

• The platform is FDA-cleared for use as a diagnostic tool.
• Designed in accordance with HIPAA and HITECH requirements, using modern encryption and authentication methods for secure connections between browsers and applications.
• Lumea notes that practices remain responsible for the security of the devices used to access the platform, including workstation security and credential management.
• Compliance documentation is available from Lumea's Information Security Officer upon request.
• Deployed across five continents with a significant concentration in the U.S. market.

Markets Served and Customer Base

• Serves urology, gastroenterology, and dermatology groups, with the urology and prostate biopsy workflow representing the area where Lumea's tissue technology was first developed and commercialized.
• Supports over half of the U.S. urology market according to the company's own description.
• Designed for both individual pathologists and larger group practices seeking a scalable entry point into digital pathology.
• TruCore Pathology is cited as a customer, with its founder describing Lumea as a solution that bridges the gap for pathologists who recognize the need to go digital but are uncertain where to begin.

Return on Investment

• Lumea states that ROI from its histology and tissue technology is typically seen within three months of initial investment.
• Broader cost savings are attributed to reductions in storage, shipping, physical slide transport, consultation costs, and turnaround times, as well as gains in diagnostic accuracy and workflow efficiency.
• The company provides a free resource called the Digital Pathologists' Playbook, a step-by-step guide covering vendor selection, equipment specifications, ROI considerations, and relevant industry events.

Lumea's leadership team includes executives across revenue, finance, innovation, marketing, operations, AI and development, product strategy, and design. The company is based at 2889 Ashton Blvd, Suite 300, Lehi, UT 84043, and can be contacted at [email protected] or by phone at 844-960-3658.

AI-generated · replace with your own

Software attributed to Lumea

• Viewer+View
• BxLinkView
• Grossing+View

Edit all with premium access